Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mehy.2020.109826 http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.109826 32416415!7207128!32416415     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Hypotheses 2020 ; 142 (ä): 109826 Nephropedia Template TP {{tp|p=32416415|t=2020. Etoposide-based therapy for severe forms of COVID-19 |pdf=|usr=}}{{32416415}} gab.com Text Etoposide-based therapy for severe forms of COVID-19 JO: Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32416415 #FOAvip The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID-19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19. Twit Text FOAVip Etoposide-based therapy for severe forms of COVID-19 ????Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32416415 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32416415 #FOAvip English Wikipedia <ref>{{Cite pmid|32416415}}</ref> Etoposide-based therapy for severe forms of COVID-19 #MMPMID32416415 Hamizi K; Aouidane S; Belaaloui G Med Hypotheses 2020[Sep]; 142 (ä): 109826 PMID32416415show ga The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment. Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID-19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19. |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy[MESH] |Dexamethasone/administration & dosage[MESH] |Epstein-Barr Virus Infections/complications[MESH] |Etoposide/*therapeutic use[MESH] |Humans[MESH] |Influenza, Human/complications[MESH] |Lymphohistiocytosis, Hemophagocytic/complications[MESH] |Models, Theoretical[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH] |Respiratory Distress Syndrome/complications[MESH]Etoposide-based therapy for severe forms of COVID-19 (epmc).pdf DeepDyve Pubget Overpricing